Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceritinib

FDA-approved product (capsule, oral), marketed as Zykadia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceritinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ceritinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Using Tumor Models to Determine Treatments

    NCT06813079 · start 2025-04-07

    Registered record
    Registry ID
    NCT06813079
    Conditions
    Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor
    Interventions
    Cobimetinib; Ponatinib; Brigatinib; Colchicine; Selinexor; Abemaciclib; Neratinib; Doxorubicin; Etoposide; Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-07
    Completion
    2028-02-17
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor
    InterventionCobimetinib; Ponatinib; Brigatinib; Colchicine +6 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    NCT05834348 · start 2023-06-23

    Registered record
    Registry ID
    NCT05834348
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    lorlatinib; crizotinib; brigatinib; ceritinib; alectinib; atezolizumab; bevacizumab; paclitaxel; carboplatin; docetaxel; erlotinib; gefitinib; afatinib; dacomitinib; osimertinib; pembrolizumab; nivolumab; entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-23
    Completion
    2024-01-23
    Enrolment
    5,279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionlorlatinib; crizotinib; brigatinib; ceritinib +14 more
    PhaseNot recorded
    Registry statusCompleted

  • Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

    NCT02645149 · start 2021-11-22

    Registered record
    Registry ID
    NCT02645149
    Conditions
    Melanoma
    Interventions
    Standard therapy or clinical trial; Matched targeted therapy; Trametinib and / or supportive care; CDK4/6 and MEK inhibitor; Compassionate Access Targeted Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-11-22
    Completion
    2026-03-06
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionStandard therapy or clinical trial; Matched targeted therapy; Trametinib and / or supportive care; CDK4/6 and MEK inhibitor +1 more
    PhasePhase 2
    Registry statusCompleted

  • Improving Public Cancer Care by Implementing Precision Medicine in Norway

    NCT04817956 · start 2021-04-01

    Registered record
    Registry ID
    NCT04817956
    Conditions
    Cancer Metastatic
    Interventions
    Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2045-04-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer Metastatic
    InterventionAtezolizumab
    PhasePhase 2
    Registry statusRecruiting

  • Antineoplastic Drugs in Elderly Patients

    NCT05467189 · start 2021-01-01

    Registered record
    Registry ID
    NCT05467189
    Conditions
    Cancer
    Interventions
    Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-01-01
    Completion
    2028-06-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionBusulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
    PhaseNot recorded
    Registry statusRecruiting

  • Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

    NCT04647110 · start 2020-12-14

    Registered record
    Registry ID
    NCT04647110
    Conditions
    ALK-positive NSCLC
    Interventions
    crizotinib; alectinib; brigatinib; ceritinib; lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-14
    Completion
    2021-03-15
    Enrolment
    549

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive NSCLC
    Interventioncrizotinib; alectinib; brigatinib; ceritinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

    NCT04115410 · start 2020-07-01

    Registered record
    Registry ID
    NCT04115410
    Conditions
    Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
    Interventions
    PD-1 inhibitor; Chemotherapy Drugs, Cancer
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-07-01
    Completion
    2021-12-31
    Enrolment
    4,724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
    InterventionPD-1 inhibitor; Chemotherapy Drugs, Cancer
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

    NCT04356118 · start 2020-06

    Registered record
    Registry ID
    NCT04356118
    Conditions
    Leptomeningeal Metastasis
    Interventions
    Recombinant Human Endostatin; intrathcal methotrexate; Targeted drugs for non-small cell lung cancer
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06
    Completion
    2023-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeptomeningeal Metastasis
    InterventionRecombinant Human Endostatin; intrathcal methotrexate; Targeted drugs for non-small cell lung cancer
    PhasePhase 4
    Registry statusUnknown

  • Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

    NCT04322890 · start 2020-04-16

    Registered record
    Registry ID
    NCT04322890
    Conditions
    Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation
    Interventions
    Osimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib.; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-04-16
    Completion
    2027-12-24
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation +1 more
    InterventionOsimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib. +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Molecular Profiling of Advanced Soft-tissue Sarcomas

    NCT03784014 · start 2019-10-19

    Registered record
    Registry ID
    NCT03784014
    Conditions
    Soft Tissue Sarcoma
    Interventions
    Nilotinib; Ceritinib; Capmatinib; Lapatinib; Trametinib; Trametinib and Dabrafenib; Olaparib and Durvalumab; Palbociclib; Glasdegib; TAS-120; Next Generation sequencing exome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-19
    Completion
    2026-01-20
    Enrolment
    603

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma
    InterventionNilotinib; Ceritinib; Capmatinib; Lapatinib +7 more
    PhasePhase 3
    Registry statusCompleted

  • Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

    NCT03737994 · start 2019-07-25

    Registered record
    Registry ID
    NCT03737994
    Conditions
    Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Alectinib; Brigatinib; Carboplatin; Ceritinib; Cisplatin; Crizotinib; Ensartinib; Lorlatinib; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-07-25
    Completion
    2026-03-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    InterventionAlectinib; Brigatinib; Carboplatin; Ceritinib +5 more
    PhasePhase 2
    Registry statusTerminated

  • Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

    NCT03611738 · start 2019-02-01

    Registered record
    Registry ID
    NCT03611738
    Conditions
    Non-small Cell Lung Cancer; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB; Stage IV Non-small Cell Lung Cancer; EGFR Negative Non-Small Cell Lung Cancer
    Interventions
    Ceritinib; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-02-01
    Completion
    2027-03
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB +2 more
    InterventionCeritinib; Docetaxel
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

    NCT03399487 · start 2018-07-24

    Registered record
    Registry ID
    NCT03399487
    Conditions
    Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
    Interventions
    LDK378(Ceritinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-07-24
    Completion
    2020-10
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Harboring ROS1 Rearrangement
    InterventionLDK378(Ceritinib)
    PhasePhase 2
    Registry statusUnknown

  • A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

    NCT03546894 · start 2018-07-23

    Registered record
    Registry ID
    NCT03546894
    Conditions
    Anaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung
    Interventions
    Brigatinib; Alectinib; Ceritinib; Lorlatinib; Any FDA Approved ALK Inhibitors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2023-02-13
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung
    InterventionBrigatinib; Alectinib; Ceritinib; Lorlatinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

    NCT03501368 · start 2018-06-27

    Registered record
    Registry ID
    NCT03501368
    Conditions
    Melanoma; Unresectable Melanoma; Advanced Melanoma
    Interventions
    Ceritinib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-27
    Completion
    2024-12-30
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Unresectable Melanoma; Advanced Melanoma
    InterventionCeritinib; Trametinib
    PhasePhase 1
    Registry statusCompleted